Cargando…
P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429267/ http://dx.doi.org/10.1097/01.HS9.0000846588.94000.04 |
| _version_ | 1784779387151843328 |
|---|---|
| author | Mai, E. K. Bertsch, U. Fenk, R. Tichy, D. Besemer, B. Dürig, J. Schroers, R. von Metzler, I. Hänel, M. Mann, C. Asemissen, A. M. Heilmeier, B. Nievergall, E. Huhn, S. Kriegsmann, K. Weinhold, N. Luntz, S. Holderrried, T. A. W. Trautmann-Grill, K. Gezer, D. Klaiber-Hakimi, M. Müller, M. Khandanpour, C. Knauf, W. Scheid, C. Munder, M. Geer, T. Riesenberg, H. Thomalla, J. Hoffmann, M. Raab, M. S. Salwender, H. J. Weisel, K. C. Goldschmidt, H. |
| author_facet | Mai, E. K. Bertsch, U. Fenk, R. Tichy, D. Besemer, B. Dürig, J. Schroers, R. von Metzler, I. Hänel, M. Mann, C. Asemissen, A. M. Heilmeier, B. Nievergall, E. Huhn, S. Kriegsmann, K. Weinhold, N. Luntz, S. Holderrried, T. A. W. Trautmann-Grill, K. Gezer, D. Klaiber-Hakimi, M. Müller, M. Khandanpour, C. Knauf, W. Scheid, C. Munder, M. Geer, T. Riesenberg, H. Thomalla, J. Hoffmann, M. Raab, M. S. Salwender, H. J. Weisel, K. C. Goldschmidt, H. |
| author_sort | Mai, E. K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429267 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94292672022-08-31 P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL Mai, E. K. Bertsch, U. Fenk, R. Tichy, D. Besemer, B. Dürig, J. Schroers, R. von Metzler, I. Hänel, M. Mann, C. Asemissen, A. M. Heilmeier, B. Nievergall, E. Huhn, S. Kriegsmann, K. Weinhold, N. Luntz, S. Holderrried, T. A. W. Trautmann-Grill, K. Gezer, D. Klaiber-Hakimi, M. Müller, M. Khandanpour, C. Knauf, W. Scheid, C. Munder, M. Geer, T. Riesenberg, H. Thomalla, J. Hoffmann, M. Raab, M. S. Salwender, H. J. Weisel, K. C. Goldschmidt, H. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429267/ http://dx.doi.org/10.1097/01.HS9.0000846588.94000.04 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Mai, E. K. Bertsch, U. Fenk, R. Tichy, D. Besemer, B. Dürig, J. Schroers, R. von Metzler, I. Hänel, M. Mann, C. Asemissen, A. M. Heilmeier, B. Nievergall, E. Huhn, S. Kriegsmann, K. Weinhold, N. Luntz, S. Holderrried, T. A. W. Trautmann-Grill, K. Gezer, D. Klaiber-Hakimi, M. Müller, M. Khandanpour, C. Knauf, W. Scheid, C. Munder, M. Geer, T. Riesenberg, H. Thomalla, J. Hoffmann, M. Raab, M. S. Salwender, H. J. Weisel, K. C. Goldschmidt, H. P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title | P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title_full | P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title_fullStr | P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title_full_unstemmed | P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title_short | P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL |
| title_sort | p930: isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed multiple myeloma patients with high-risk cytogenetics: a subgroup analysis from the gmmg-hd7 trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429267/ http://dx.doi.org/10.1097/01.HS9.0000846588.94000.04 |
| work_keys_str_mv | AT maiek p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT bertschu p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT fenkr p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT tichyd p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT besemerb p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT durigj p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT schroersr p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT vonmetzleri p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT hanelm p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT mannc p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT asemissenam p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT heilmeierb p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT nievergalle p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT huhns p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT kriegsmannk p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT weinholdn p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT luntzs p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT holderrriedtaw p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT trautmanngrillk p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT gezerd p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT klaiberhakimim p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT mullerm p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT khandanpourc p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT knaufw p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT scheidc p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT munderm p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT geert p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT riesenbergh p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT thomallaj p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT hoffmannm p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT raabms p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT salwenderhj p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT weiselkc p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial AT goldschmidth p930isatuximablenalidomidebortezomibanddexamethasoneasinductiontherapyfornewlydiagnosedmultiplemyelomapatientswithhighriskcytogeneticsasubgroupanalysisfromthegmmghd7trial |